TY - JOUR
T1 - Modern-day cardio-oncology
T2 - a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’
AU - Anker, Markus S.
AU - Lena, Alessia
AU - the Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology
AU - Hadzibegovic, Sara
AU - Belenkov, Yury
AU - Bergler-Klein, Jutta
AU - de Boer, Rudolf A.
AU - Cohen-Solal, Alain
AU - Farmakis, Dimitrios
AU - von Haehling, Stephan
AU - López-Fernández, Teresa
AU - Pudil, Radek
AU - Suter, Thomas
AU - Tocchetti, Carlo G.
AU - Lyon, Alexander R.
N1 - Publisher Copyright:
© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
PY - 2018/12
Y1 - 2018/12
N2 - During the ‘Heart Failure and World Congress on Acute Heart Failure 2018’, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.
AB - During the ‘Heart Failure and World Congress on Acute Heart Failure 2018’, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.
UR - http://www.scopus.com/inward/record.url?scp=85058899793&partnerID=8YFLogxK
U2 - 10.1002/ehf2.12386
DO - 10.1002/ehf2.12386
M3 - Review article
C2 - 30570223
AN - SCOPUS:85058899793
SN - 2055-5822
VL - 5
SP - 1083
EP - 1091
JO - ESC heart failure
JF - ESC heart failure
IS - 6
ER -
